329 related articles for article (PubMed ID: 36078039)
1. IRF8: Mechanism of Action and Health Implications.
Moorman HR; Reategui Y; Poschel DB; Liu K
Cells; 2022 Aug; 11(17):. PubMed ID: 36078039
[TBL] [Abstract][Full Text] [Related]
2. The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production.
Netherby CS; Messmer MN; Burkard-Mandel L; Colligan S; Miller A; Cortes Gomez E; Wang J; Nemeth MJ; Abrams SI
J Immunol; 2017 May; 198(10):4129-4139. PubMed ID: 28356386
[TBL] [Abstract][Full Text] [Related]
3. Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression.
Patel A; Oba T; Kajihara R; Yokoi T; Abrams SI; Ito F
J Immunol; 2021 Sep; 207(5):1298-1309. PubMed ID: 34362833
[TBL] [Abstract][Full Text] [Related]
4. IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation.
Paschall AV; Zhang R; Qi CF; Bardhan K; Peng L; Lu G; Yang J; Merad M; McGaha T; Zhou G; Mellor A; Abrams SI; Morse HC; Ozato K; Xiong H; Liu K
J Immunol; 2015 Mar; 194(5):2369-79. PubMed ID: 25646302
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis.
Ibrahim ML; Klement JD; Lu C; Redd PS; Xiao W; Yang D; Browning DD; Savage NM; Buckhaults PJ; Morse HC; Liu K
Cell Rep; 2018 Dec; 25(11):3036-3046.e6. PubMed ID: 30540937
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease.
Netherby CS; Abrams SI
Cancer Immunol Immunother; 2017 Aug; 66(8):989-996. PubMed ID: 28224211
[TBL] [Abstract][Full Text] [Related]
7. Interferon regulatory factor 4 (IRF4) controls myeloid-derived suppressor cell (MDSC) differentiation and function.
Nam S; Kang K; Cha JS; Kim JW; Lee HG; Kim Y; Yang Y; Lee MS; Lim JS
J Leukoc Biol; 2016 Dec; 100(6):1273-1284. PubMed ID: 27601624
[TBL] [Abstract][Full Text] [Related]
8. Distinct Role of CD11b
Wu SY; Chiang CS
Cells; 2019 Dec; 9(1):. PubMed ID: 31878276
[TBL] [Abstract][Full Text] [Related]
9. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
10. Age-related expansion and increased osteoclastogenic potential of myeloid-derived suppressor cells.
Li Z; Zhao Y; Chen Z; Katz J; Michalek SM; Li Y; Zhang P
Mol Immunol; 2021 Sep; 137():187-200. PubMed ID: 34274794
[TBL] [Abstract][Full Text] [Related]
11. SETD1B Activates iNOS Expression in Myeloid-Derived Suppressor Cells.
Redd PS; Ibrahim ML; Klement JD; Sharman SK; Paschall AV; Yang D; Nayak-Kapoor A; Liu K
Cancer Res; 2017 Jun; 77(11):2834-2843. PubMed ID: 28381543
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of B220
Zhang Z; Huang X; Wang E; Huang Y; Yang R
Oncoimmunology; 2021 Apr; 10(1):1912472. PubMed ID: 33948392
[TBL] [Abstract][Full Text] [Related]
13. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion.
Klement JD; Paschall AV; Redd PS; Ibrahim ML; Lu C; Yang D; Celis E; Abrams SI; Ozato K; Liu K
J Clin Invest; 2018 Dec; 128(12):5549-5560. PubMed ID: 30395540
[TBL] [Abstract][Full Text] [Related]
14. CD205
Fu C; Fu Z; Jiang C; Xia C; Zhang Y; Gu X; Zheng K; Zhou D; Tang S; Lyu S; Ma S
Cancer Sci; 2021 Mar; 112(3):1011-1025. PubMed ID: 33368883
[TBL] [Abstract][Full Text] [Related]
15. CCR5 Directs the Mobilization of CD11b
Hawila E; Razon H; Wildbaum G; Blattner C; Sapir Y; Shaked Y; Umansky V; Karin N
Cell Rep; 2017 Nov; 21(8):2212-2222. PubMed ID: 29166611
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.
Waight JD; Netherby C; Hensen ML; Miller A; Hu Q; Liu S; Bogner PN; Farren MR; Lee KP; Liu K; Abrams SI
J Clin Invest; 2013 Oct; 123(10):4464-78. PubMed ID: 24091328
[TBL] [Abstract][Full Text] [Related]
17. Simple protocol for measuring CD11b+ GR-1+ (Ly6C+/Ly6G+) myeloid cells from a minimum volume of mouse peripheral blood.
Borgna E; Gamba JC; Prochetto E; Marcipar I; Cabrera G
Methods Cell Biol; 2024; 184():59-68. PubMed ID: 38555158
[TBL] [Abstract][Full Text] [Related]
18. An In Vivo Mouse Model for Chronic Inflammation-Induced Immune Suppression: A "Factory" for Myeloid-Derived Suppressor Cells (MDSCs).
Ben-Meir K; Twaik N; Meirow Y; Baniyash M
Curr Protoc; 2022 Sep; 2(10):e558. PubMed ID: 36239438
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer.
Hu X; Bardhan K; Paschall AV; Yang D; Waller JL; Park MA; Nayak-Kapoor A; Samuel TA; Abrams SI; Liu K
J Biol Chem; 2013 Jun; 288(26):19103-15. PubMed ID: 23677993
[TBL] [Abstract][Full Text] [Related]
20. ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer.
Chen H; Yang K; Pang L; Fei J; Zhu Y; Zhou J
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
